Skip to content

Antithymocyte globulin usefullness in treatment of low blood cell count

A phase IV multicentre study to confirm the safety and efficacy of Equine Antithymocyte globulin along with cyclosporine in patients with moderate to severe aplastic anaemia - ATG in AA

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/03/002498
Enrollment
15
Registered
2012-03-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D60-D64- Aplastic and other anemias and other bone marrow failure syndromes Health Condition 2: null- Aplastic Anemia

Interventions

Intervention1: Thymogam: Thymogam is a sterile, transparent aqueous solution containing Antithymocyte globulin. Thymogam is obtained by processing hyper-immune serum of horses immunized with human th

Sponsors

Bharat Serums and Vaccines Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Acquired aplastic anaemia 2. Age above 2 years 3. Hypocellular bone marrow- 4. With any severity of disease

Exclusion criteria

Exclusion criteria: a. History of cancer b. Creatinine > 2.5 times above the normal limit c. HIV positive d. Clonal disorder e. Pregnancy a. Participation in another investigational study within 30 days before the current study.

Design outcomes

Primary

MeasureTime frame
Complete remission A.Transfusion independence B. Hb â?¥ 11 g/Dl C. Neutrophils 1.5 Ã? 109/L D. Platelets 100 Ã? 109/L.) ii. Partial remission A. Transfusion independence B. Hb â?¥ 8 g/dL C. Neutrophils0.5 Ã? 109/L D. Platelets 20 Ã? 109/L.) iii. Non responsive A. Transfusion dependence was taken as evidence of no response. Timepoint: Day 90 / Day 180

Secondary

MeasureTime frame
i. Incidence/Time to relapse ii. Mortality Timepoint: Day 90/ Day 180

Countries

India

Contacts

Public ContactMs Najy Turakhia

Seth GS Medical College and KEM Hospital

farahjijina@hotmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 20, 2026